
|Articles|May 1, 2004
FDA gives nod; Hylaform joins ranks of fillers
Santa Barbara, Calif. -- The U.S. Food and Drug Administration late last month granted approval for Inamed Corp.'s Hylaform (Hylan-B gel). The hyaluronic-acid-based dermal filler is indicated for injection into the deep dermis for correction of moderate-to-severe facial wrinkles and folds. The move, while expected, adds a few wrinkles of its own to the growing U.S. market for dermal fillers.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















